Chey Tae-won, chairman of SK Group, made a big bet in establishing a stronger presence in the biomedicine market.
SK Biotek, a 100-percent-owned subsidiary of SK Corp., acquired the Ireland plant of a multinational pharmaceutical company Bristol-Myers Squibb on June 18, gaining a foothold to create a presence in the European market.
Chey, who had started investing in the biomedicine business 20 years ago, has beefed up related businesses thereafter.
SK is rare among Korea's major conglomerates. It has an extensive range of biomedicine subsidiaries, including those with specialty in the production of active pharmaceutical ingredients, vaccines, finished drugs, and new drug developments.
SK's biomedicine subsidiaries are showing gradual improvement in performance, with SK Biotek passing the 100-billion-won mark in annual sales last year.
With the history of 130 years, Bristol-Myers Squibb is a global pharmaceutical company with its annual sales estimated at about $19 billion. With the latest acquisition of the Ireland plant, SK Biotek expects to be able to grow at a faster pace in Europe.
National Pension Service’s (NPS) recent invitation for investment proposals to domestic private equity and venture capital funds, which amounts to 650 billion won ($577 million), has met with a lukewarm response from fund houses, amid concerns about the $500 billion&hellip
Korea Investment Corporation (KIC) Chief Investment Officer Shinwoo Kang will give a keynote speech in a global real estate and infrastructure summit on Oct. 25 in Seoul, where key investment decision-makers of South Korea’s biggest asset owners are set to&hellip
Asia-based investment firm Pacific Alliance Group (PAG) has bought an office building in southern Seoul from a fund led by the Public Officials Benefit Association (POBA) for around 310 billion won ($273 million), at a time when the growing nuclear&hellip